

Sian Fereday

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6491651/sian-fereday-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

7,595
citations

27
h-index

50
g-index

50
ext. papers

9,522
ext. citations

10.8
avg, IF

7.08
L-index

#	Paper	IF	Citations
48	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102108	2.2	
47	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. <i>Nature Communications</i> , 2021 , 12, 3039	17.4	5
46	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1669-1680	4	2
45	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
44	Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision. <i>Biomarkers in Medicine</i> , 2021 , 15, 1111-1122	2.3	1
43	The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer 2021 , 43-53		
42	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020 , 31, 1240-1250	10.3	37
41	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
40	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020 , 123, 793-802	8.7	16
39	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020 , 578, 82-93	50.4	840
38	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020 , 156, 552-560	4.9	21
37	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3935	17.4	59
36	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 339-348	31.3	17
35	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019 , 25, 3962-3973	12.9	16
34	Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. <i>Nature Communications</i> , 2019 , 10, 1295	17.4	66
33	Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. <i>PLoS ONE</i> , 2019 , 14, e0211504	3.7	4
32	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320	6.4	14

31	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 680-688	4	1
30	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 569-580	12.9	46
29	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 250-261	5.3	38
28	Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-14	3.6	9
27	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , 2018 , 150, 239-246	4.9	17
26	Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1274-1280	2.2	122
25	and Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017 , 77, 4268-4278	10.1	32
24	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. <i>Human Molecular Genetics</i> , 2016 , 25, 5460-5471	5.6	20
23	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016 , 142, 458-64	4.9	13
22	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1495-503	6.1	13
21	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4	890
20	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 652-7	12.9	107
19	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). <i>Gynecologic Oncology</i> , 2014 , 133, 16-22	4.9	36
18	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , 2014 , 111, 2297-307	8.7	49
17	Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. <i>Clinical Cancer Research</i> , 2014 , 20, 6618-30	12.9	66
16	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology, The</i> , 2013 , 14, 853-62	21.7	248
15	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013 , 131, 8-14	4.9	39
14	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. <i>Journal of Pathology</i> , 2013 , 229, 111-20	9.4	139

13	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 2013 , 123, 517-25	15.9	371
12	High levels of genomic aberrations in serous ovarian cancers are associated with better survival. <i>PLoS ONE</i> , 2013 , 8, e54356	3.7	14
11	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2654-63	2.2	810
10	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , 2012 , 72, 4060-73	10.1	73
9	Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2253-8	2.2	37
8	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , 2010 , 363, 1532-43	59.2	1208
7	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. <i>Journal of Pathology</i> , 2010 , 221, 49-56	9.4	485
6	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 1417-27	12.9	217
5	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , 2008 , 14, 5198-208	12.9	1044
4	ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 5594-601	12.9	83
3	Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. <i>Molecular Cancer Research</i> , 2008 , 6, 1678-90	6.6	93
2	Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. <i>Breast Cancer Research</i> , 2006 , 8, R12	8.3	125
1	The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. <i>Breast Cancer Research</i> , 2001 , 3, 346-9	8.3	12